Expanded Access to REGN4461 for Patients With Lipodystrophy or Monogenic Obesity With Complications of Leptin Deficiency or Deficient Leptin Signaling

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Provide Expanded Access to REGN4461 for patients with lipodystrophy or monogenic obesity with complications of leptin deficiency or deficient leptin signaling

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Expanded Access requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lipodystrophy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Leptin (LEP) Leptin Receptors (LEPR)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

REGN4461

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

mibavademab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Eligible Sex

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Requests for compassionate use must be initiated by a treating physician. Physicians should contact

Role: CONTACT

Phone: 844-734-6643

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R4461-LEPR

Identifier Type: -

Identifier Source: org_study_id